These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 12617036)

  • 1. [Molecular chaperone HSP90 as a novel target for cancer chemotherapy].
    Miyata Y
    Nihon Yakurigaku Zasshi; 2003 Jan; 121(1):33-42. PubMed ID: 12617036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents.
    Miyata Y
    Curr Pharm Des; 2005; 11(9):1131-8. PubMed ID: 15853661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effects of Hsp90 inhibition on protein kinases regulating signal transduction pathways required for myoblast differentiation.
    Yun BG; Matts RL
    Exp Cell Res; 2005 Jul; 307(1):212-23. PubMed ID: 15922741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond.
    Georgakis GV; Younes A
    Future Oncol; 2005 Apr; 1(2):273-81. PubMed ID: 16555999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hsp90/p50cdc37 is required for mixed-lineage kinase (MLK) 3 signaling.
    Zhang H; Wu W; Du Y; Santos SJ; Conrad SE; Watson JT; Grammatikakis N; Gallo KA
    J Biol Chem; 2004 May; 279(19):19457-63. PubMed ID: 15001580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered states: selectively drugging the Hsp90 cancer chaperone.
    Workman P
    Trends Mol Med; 2004 Feb; 10(2):47-51. PubMed ID: 15106614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Involvement of Hsp90 in the quality control of signal transducing proteins].
    Miyata Y
    Tanpakushitsu Kakusan Koso; 2004 May; 49(7 Suppl):862-6. PubMed ID: 15168480
    [No Abstract]   [Full Text] [Related]  

  • 8. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin.
    Roe SM; Prodromou C; O'Brien R; Ladbury JE; Piper PW; Pearl LH
    J Med Chem; 1999 Jan; 42(2):260-6. PubMed ID: 9925731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stability of the Peutz-Jeghers syndrome kinase LKB1 requires its binding to the molecular chaperones Hsp90/Cdc37.
    Nony P; Gaude H; Rossel M; Fournier L; Rouault JP; Billaud M
    Oncogene; 2003 Dec; 22(57):9165-75. PubMed ID: 14668798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
    Georgakis GV; Li Y; Rassidakis GZ; Martinez-Valdez H; Medeiros LJ; Younes A
    Clin Cancer Res; 2006 Jan; 12(2):584-90. PubMed ID: 16428504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer.
    Bagatell R; Khan O; Paine-Murrieta G; Taylor CW; Akinaga S; Whitesell L
    Clin Cancer Res; 2001 Jul; 7(7):2076-84. PubMed ID: 11448926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A model for the cytoplasmic trafficking of signalling proteins involving the hsp90-binding immunophilins and p50cdc37.
    Pratt WB; Silverstein AM; Galigniana MD
    Cell Signal; 1999 Dec; 11(12):839-51. PubMed ID: 10659992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Heat shock protein 90: novel target for cancer therapy].
    Chen Y; Ding J
    Ai Zheng; 2004 Aug; 23(8):968-74. PubMed ID: 15301726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors.
    Kamal A; Thao L; Sensintaffar J; Zhang L; Boehm MF; Fritz LC; Burrows FJ
    Nature; 2003 Sep; 425(6956):407-10. PubMed ID: 14508491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic and diagnostic implications of Hsp90 activation.
    Kamal A; Boehm MF; Burrows FJ
    Trends Mol Med; 2004 Jun; 10(6):283-90. PubMed ID: 15177193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity.
    Neckers L; Schulte TW; Mimnaugh E
    Invest New Drugs; 1999; 17(4):361-73. PubMed ID: 10759403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Hsp90 chaperone complex as a novel target for cancer therapy.
    Goetz MP; Toft DO; Ames MM; Erlichman C
    Ann Oncol; 2003 Aug; 14(8):1169-76. PubMed ID: 12881371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific association of a set of molecular chaperones including HSP90 and Cdc37 with MOK, a member of the mitogen-activated protein kinase superfamily.
    Miyata Y; Ikawa Y; Shibuya M; Nishida E
    J Biol Chem; 2001 Jun; 276(24):21841-8. PubMed ID: 11278794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin.
    Schulte TW; Neckers LM
    Cancer Chemother Pharmacol; 1998; 42(4):273-9. PubMed ID: 9744771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure and in vivo function of Hsp90.
    Pearl LH; Prodromou C
    Curr Opin Struct Biol; 2000 Feb; 10(1):46-51. PubMed ID: 10679459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.